News
12d
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
5d
Zacks Investment Research on MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...
Bank of America Securities analyst Tim Anderson maintained a Buy rating on Merck & Company today. The company’s shares opened today at $83.96. Elevate Your Investing Strategy: T ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results